Cargando…
P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
INTRODUCTION: Measurement of amyloid beta (Aβ40 and Aβ42) and tau (phosphorylated tau [p‐tau] and total tau [t‐tau]) in cerebrospinal fluid (CSF) can be utilized to differentiate clinical and preclinical Alzheimer's disease dementia (AD) from other neurodegenerative processes. METHODS: CSF biom...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129859/ https://www.ncbi.nlm.nih.gov/pubmed/34027020 http://dx.doi.org/10.1002/dad2.12190 |
_version_ | 1783694392697028608 |
---|---|
author | Campbell, Michelle R. Ashrafzadeh‐Kian, Susan Petersen, Ronald C. Mielke, Michelle M. Syrjanen, Jeremy A. van Harten, Argonde C. Lowe, Val J. Jack, Clifford R. Bornhorst, Joshua A. Algeciras‐Schimnich, Alicia |
author_facet | Campbell, Michelle R. Ashrafzadeh‐Kian, Susan Petersen, Ronald C. Mielke, Michelle M. Syrjanen, Jeremy A. van Harten, Argonde C. Lowe, Val J. Jack, Clifford R. Bornhorst, Joshua A. Algeciras‐Schimnich, Alicia |
author_sort | Campbell, Michelle R. |
collection | PubMed |
description | INTRODUCTION: Measurement of amyloid beta (Aβ40 and Aβ42) and tau (phosphorylated tau [p‐tau] and total tau [t‐tau]) in cerebrospinal fluid (CSF) can be utilized to differentiate clinical and preclinical Alzheimer's disease dementia (AD) from other neurodegenerative processes. METHODS: CSF biomarkers were measured in 150 participants from the Mayo Clinic Study of Aging and the Alzheimer's Disease Research Center. P‐tau/Aβ42 (Roche Elecsys, Fujirebio LUMIPULSE) and Aβ42/40 (Fujirebio LUMIPULSE) ratios were compared to one another and to amyloid positron emission tomography (PET) classification. RESULTS: Strong correlation was observed between LUMIPULSE p‐tau/Aβ42 and Aβ42/40, as well as Elecsys and LUMIPULSE p‐tau/Aβ42 and Aβ42/40 (Spearman's ρ = –0.827, –0.858, and 0.960, respectively). Concordance between LUMIPULSE p‐tau/Aβ42 and Aβ42/40 was 96% and between Elecsys p‐tau/Aβ42 and both LUMIPULSE ratios was 97%. All ratios had > 94% overall, positive, and negative percent agreement with amyloid PET classification. DISCUSSION: These data suggest that p‐tau/Aβ42 and Aβ42/40 ratios provide similar clinical information in the assessment of amyloid pathology. |
format | Online Article Text |
id | pubmed-8129859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81298592021-05-21 P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status Campbell, Michelle R. Ashrafzadeh‐Kian, Susan Petersen, Ronald C. Mielke, Michelle M. Syrjanen, Jeremy A. van Harten, Argonde C. Lowe, Val J. Jack, Clifford R. Bornhorst, Joshua A. Algeciras‐Schimnich, Alicia Alzheimers Dement (Amst) Cerebrospinal Fluid Biomarkers INTRODUCTION: Measurement of amyloid beta (Aβ40 and Aβ42) and tau (phosphorylated tau [p‐tau] and total tau [t‐tau]) in cerebrospinal fluid (CSF) can be utilized to differentiate clinical and preclinical Alzheimer's disease dementia (AD) from other neurodegenerative processes. METHODS: CSF biomarkers were measured in 150 participants from the Mayo Clinic Study of Aging and the Alzheimer's Disease Research Center. P‐tau/Aβ42 (Roche Elecsys, Fujirebio LUMIPULSE) and Aβ42/40 (Fujirebio LUMIPULSE) ratios were compared to one another and to amyloid positron emission tomography (PET) classification. RESULTS: Strong correlation was observed between LUMIPULSE p‐tau/Aβ42 and Aβ42/40, as well as Elecsys and LUMIPULSE p‐tau/Aβ42 and Aβ42/40 (Spearman's ρ = –0.827, –0.858, and 0.960, respectively). Concordance between LUMIPULSE p‐tau/Aβ42 and Aβ42/40 was 96% and between Elecsys p‐tau/Aβ42 and both LUMIPULSE ratios was 97%. All ratios had > 94% overall, positive, and negative percent agreement with amyloid PET classification. DISCUSSION: These data suggest that p‐tau/Aβ42 and Aβ42/40 ratios provide similar clinical information in the assessment of amyloid pathology. John Wiley and Sons Inc. 2021-05-18 /pmc/articles/PMC8129859/ /pubmed/34027020 http://dx.doi.org/10.1002/dad2.12190 Text en © 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Cerebrospinal Fluid Biomarkers Campbell, Michelle R. Ashrafzadeh‐Kian, Susan Petersen, Ronald C. Mielke, Michelle M. Syrjanen, Jeremy A. van Harten, Argonde C. Lowe, Val J. Jack, Clifford R. Bornhorst, Joshua A. Algeciras‐Schimnich, Alicia P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status |
title | P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status |
title_full | P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status |
title_fullStr | P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status |
title_full_unstemmed | P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status |
title_short | P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status |
title_sort | p‐tau/aβ42 and aβ42/40 ratios in csf are equally predictive of amyloid pet status |
topic | Cerebrospinal Fluid Biomarkers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129859/ https://www.ncbi.nlm.nih.gov/pubmed/34027020 http://dx.doi.org/10.1002/dad2.12190 |
work_keys_str_mv | AT campbellmicheller ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus AT ashrafzadehkiansusan ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus AT petersenronaldc ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus AT mielkemichellem ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus AT syrjanenjeremya ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus AT vanhartenargondec ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus AT lowevalj ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus AT jackcliffordr ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus AT bornhorstjoshuaa ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus AT algecirasschimnichalicia ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus |